

CORRECTION

Open Access



# Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

E. C. de Heer<sup>1†</sup>, C. E. Zois<sup>2,3,4\*\*</sup>, E. Bridges<sup>2†</sup>, B. van der Vegt<sup>5</sup>, H. Sheldon<sup>2</sup>, W. A. Veldman<sup>1</sup>, M. C. Zwager<sup>5</sup>, T. van der Sluis<sup>5</sup>, S. Haider<sup>6</sup>, T. Morita<sup>7</sup>, O. Baba<sup>7</sup>, C. P. Schröder<sup>1,8</sup>, S. de Jong<sup>1</sup>, A. L. Harris<sup>2</sup> and M. Jalving<sup>1\*</sup>

**Correction:** *J Exp Clin Cancer Res* 42, 143 (2023)  
<https://doi.org/10.1186/s13046-023-02715-z>

Following publication of the original article [1], an error was identified in Additional File 8: Fig. 6c. HCC1806 should have been U87MG. The correct Additional File 8: Fig. 6c caption should be:

(c) Well confluency of U87MG-shCtrl and -shGYS1 cells treated with different concentrations of GTPP,

cultured in 5.6 mM glucose complete DMEM, was measured by Incucyte every 3 h.

The correction does not affect the overall Conclusion of the article. The original article has been corrected.

Published online: 28 August 2023

<sup>†</sup>E.C. de Heer, C.E. Zois, E. Bridges contributed equally to this work.

The online version of the original article can be found at <https://doi.org/10.1186/s13046-023-02715-z>.

\*Correspondence:

C. E. Zois  
christos.zois@oncology.ox.ac.uk

M. Jalving  
m.jalving@umcg.nl

<sup>1</sup>Department of Medical Oncology, University of Groningen, University Medical Center Groningen, PO Box 30.001, Groningen 9700 RB, The Netherlands

<sup>2</sup>Department of Oncology, Weatherall Institute of Molecular Medicine, Hypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, University of Oxford, Oxford OX3 9DS, UK

<sup>3</sup>Department of Radiotherapy and Oncology, School of Health, Democritus University of Thrace, Alexandroupolis, Greece

<sup>4</sup>Department of Oncology, MRC Weatherall Institute of Molecular Medicine, Molecular Oncology Laboratories, John Radcliffe Hospital, Oxford University, Oxford OX3 9DS, UK

<sup>5</sup>Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

<sup>6</sup>The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK

<sup>7</sup>Tokushima University Graduate School, 3-18-15, Kuramoto-Cho, Tokushima 770-8504, Japan

<sup>8</sup>Department of Medical Oncology, Antoni Van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands

## References

1. de Heer EC, Zois CE, Bridges E, et al. Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer. *J Exp Clin Cancer Res.* 2023;42:143. <https://doi.org/10.1186/s13046-023-02715-z>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

